70-year-old acute myeloid leukemia can be treated with chemotherapy and supportive therapy to slow down the disease process as well as prolong survival, but the appropriate chemotherapy regimen and intensity should be selected according to the physical condition.
For the study of elderly acute myeloid leukemia (AML) patient population, this part of the patient can benefit from chemotherapy, i.e., chemotherapy can prolong the survival and improve the quality of life of elderly AML patients, so chemotherapy is still the first recommendation.
However, elderly patients have poor organ function, poor tolerance to anemia, thrombocytopenia, etc., and more comorbidities, so the chemotherapy regimen and dosage for 70-year-old AML patients have their own characteristics, and need to be reduced or given a small dose of demethylation therapy (e.g., azacitidine) or combined with Bcl-2 inhibitor (e.g., vinaclatide) chemotherapy and so on.
In addition, extra attention should be paid to supportive therapy, such as active anti-infection, protection of organ function, attention to cardiac loading when transfusing blood products, etc. 70-year-old patients are poorly tolerant to hematopoietic stem cell transplantation, and need to be carefully selected according to the patient’s condition.
70-year-old acute myeloid leukemia is recommended to choose the appropriate treatment under the guidance of a specialist, the above drugs need to be used under the guidance of a doctor.